Generic Medication Name |
Pharmacological Category (up-to-date) |
Formulary Brief (if available) |
Notes / Miscellaneous |
Similar NCF Medications |
Active? |
Acetaminophen |
Analgesic, Miscellaneous |
Short-Acting Opioids (2014) |
|
|
Yes |
Adalimumab-bwwd (Hadlima™) |
Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent |
NPTC Update (Jan 2024) |
|
Etanercept |
Yes |
Albuterol nebulized solution |
Beta2 Agonist |
Asthma & COPD Guidelines Review (2019) |
|
|
Yes |
Albuterol, metered dose inhaler (MDI) |
Beta2 Agonist |
Asthma & COPD Guidelines Review (2019) |
*Any product* |
|
Yes |
Alendronate |
Bisphosphonate Derivative |
Osteoporosis (2016) |
|
|
Yes |
Allopurinol |
Antigout Agent; Xanthine Oxidase Inhibitor |
Gout (2016) |
|
|
Yes |
Alogliptin |
Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor |
DPP-IV Inhibitors (2019) |
|
|
Yes |
Amitriptyline |
Antidepressant, Tricyclic |
Bipolar Disorder (2022) |
|
Nortriptyline |
Yes |
Amlodipine |
Antihypertensive; Calcium Channel Blocker, Dihydropyridine |
Hypertension (2022) |
|
Diltiazem |
Yes |
Amoxicillin |
Antibiotic, Penicillin |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
Amoxicillin and Clavulanate; Penicillin G benzathine; Penicllin V potassium |
Yes |
Amoxicillin and Clavulanate |
Antibiotic, Penicillin |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
Amoxicillin; Penicillin G benzathine; Penicllin V potassium |
Yes |
Anastrozole |
Antineoplastic Agent, Aromatase Inhibitor |
NPTC Update Spring 2021 |
|
|
Yes |
Angiotensin receptor blocker |
===REMOVED from NCF=== (see Losartan) |
Angiotensin II Receptor Antagonists (2014) |
Removed April 2012 |
Losartan |
No |
Apixaban |
Anticoagulant; Direct Oral Anticoagulant (DOAC); Factor Xa Inhibitor |
Direct Oral Anticoagulants (2017) |
|
Warfarin |
Yes |
Aripiprazole lauroxil |
Antipsychotic, Atypical (Second Generation) - Injectable |
Long-Acting Injectable Antipsychotics (2020) |
Injectable |
Haloperidol decanoate |
Yes |
Artificial Tear substitute, ophthalmic (preservative free) |
Ophthalmic Agent, Miscellaneous |
Ocular Treatments (2022) |
*Any Preservative-Free product* |
Ciprofloxacin, Ophthalmic Solution; Corticosteroid (Ophthalmic) - Low Potency; Polymyxin B/trimethoprim, Ophthalmic Solution |
Yes |
Aspirin |
Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate |
Pregnancy & Prenatal Care (2021) |
|
|
Yes |
Atenolol |
Antihypertensive; Beta-Blocker, Beta1 Selective |
Hypertension (2022) |
|
Propranolol |
Yes |
Atomoxetine |
Norepinephrine Reuptake Inhibitor, Selective |
ADHD (Jan 2020) |
|
Dextroamphetamine / Amphetamine (immediate release); Dextroamphetamine / Amphetamine (long-acting); Methylphenidate (immediate release); Methylphenidate (long-acting) |
Yes |
Atorvastatin |
Antilipemic Agent, HMG-CoA Reductase Inhibitor |
Hyperlipidemia (2022) |
|
Pravastatin; Rosuvastatin; Simvastatin |
Yes |
Atypical antipsychotic |
Antipsychotic, Atypical |
Bipolar Disorders (2022) |
*Any product* |
Aripiprazole lauroxil; Haloperidol decanoate |
Yes |
Azathioprine -OR- Mercaptopurine |
Immunosuppresant Agent |
Inflammatory Bowel Disease (2023) |
|
Methotrexate; Sulfasalazine |
Yes |
Azithromycin |
Antibiotic, Macrolide |
STIs - PART 1 (2021) |
|
|
Yes |
Benzoyl Peroxide |
Topical Skin Product, Acne |
Acne Treatment (2020) |
|
Benzoyl Peroxide AND Clindamycin, topical combination |
Yes |
Benzoyl Peroxide AND Clindamycin, topical combination |
Topical Skin Product, Acne; Topical Skin Product, Acne (Lincosamide Antibiotic) |
Acne Treatment (2020) |
|
Benzoyl Peroxide |
Yes |
Beta-3 agonist, Any |
Beta3 Agonist |
Urinary Incontinence (2023) |
Either mirabegron -or- vibegron |
Oxybutynin, extended-release; Oxybutynin, immediate-release |
Yes |
Bictegravir/Emtricitabine/Tenofovir alafenamide |
Antiretroviral, Integrase Inhibitor (Anti-HIV) |
HIV Treatment (2019) |
|
Dolutegravir/abacavir/lamivudine; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir |
Yes |
Bismuth subsalicylate |
Antidiarrheal |
Helicobacter pylori Treatment (2023) |
|
Loperamide |
Yes |
Bumetanide -OR- Torsemide |
Antihypertensive |
Heart Failure with Preserved Ejection Fraction (HFpEF) (2022) |
|
Furosemide; Torsemide -OR- Bumetanide |
Yes |
Buprenorphine, long-acting (**REMS drug**) |
Analgesic, Opioid; Analgesic, Opioid Partial Agonist |
MAT for OUD (2021) |
Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** |
Buprenorphine, short-acting (**REMS drug**); Buprenorphine-Naloxone (**REMS drug**) |
Yes |
Buprenorphine, short-acting (**REMS drug**) |
Analgesic, Opioid; Analgesic, Opioid Partial Agonist |
MAT for OUD (2021) |
Any formulation; Restricted to treatment of Opioid Use Disorder; **See REMS here** |
Buprenorphine, long-acting (**REMS drug**); Buprenorphine-Naloxone (**REMS drug**) |
Yes |
Buprenorphine-Naloxone (**REMS drug**) |
Analgesic, Opioid; Analgesic, Opioid Partial Agonist |
MAT for OUD (2021) |
**See REMS here** |
Naloxone |
Yes |
Bupropion |
Antidepressant, Dopamine/Norepinephrine-Reuptake Inhibitor; Smoking Cessation Aid |
Stimulant Use Disorder (2022) |
|
Varenicline; Venlafaxine |
Yes |
Calcium |
Electrolyte Supplement |
Osteoporosis (2016) |
*Any formulation* |
|
Yes |
Carbamazepine |
Anticonvulsant, Miscellaneous |
Bipolar Disorder (2022) |
|
Divalproex; Lamotrigine; Levetiracetam; Phenytoin; Topiramate |
Yes |
Carbidopa-Levodopa, immediate-release |
Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor |
Parkinson's Disease (2019) |
|
|
Yes |
Carvedilol, immediate-release |
Antihypertensive; Beta-Blocker with Alpha-Blocking Activity |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
Atenolol; Propranolol |
Yes |
Cefdinir |
Antibiotic, Cephalosporin (Third Generation) |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
Cefixime; Ceftriaxone Injection; Cephalexin |
Yes |
Cefixime |
Antibiotic, Cephalosporin (Third Generation) |
STIs - PART 1 (2021) |
For outpatient treatment of gonorrhea for Expedited Partner Therapy or when injection therapy is not possible |
Cefdinir; Ceftriaxone Injection; Cephalexin |
Yes |
Ceftriaxone, injection |
Antibiotic, Cephalosporin (Third Generation) |
STIs - PART 1 (2021) |
|
Cefdinir; Cefixime; Cephalexin |
Yes |
Cephalexin |
Antibiotic, Cephalosporin (First Generation) |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
Cefdinir; Cefixime; Ceftriaxone Injection |
Yes |
Chlorthalidone |
Antihypertensive; Thiazide-Related Diuretic |
Hypertension (2022) |
|
Hydrochlorothiazide |
Yes |
Ciprofloxacin, ophthalmic solution |
Antibiotic, Ophthalmic Fluoroquinolone |
Ocular Treatments (2022) |
|
Artificial Tear substitute, ophthalmic (preservative free); Corticosteroid (Ophthalmic) - Low Potency; Polymyxin B/trimethoprim, Ophthalmic Solution |
Yes |
Ciprofloxacin, oral |
Antibiotic, Fluoroquinolone |
Male Genitourinary Infections (Nov 2022) |
|
|
Yes |
Citalopram |
Antidepressant, Selective Serotonin Reuptake Inhibitor |
Bipolar Disorder (2022) |
|
Escitalopram; Fluoxetine; Paroxetine; Sertraline |
Yes |
Clindamycin |
Antibiotic, Lincosamide |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
|
Yes |
Clindamycin, topical |
===REMOVED from NCF=== (See Benzoyl Peroxide AND Clindamycin, topical combination) |
|
Removed January 2020 |
|
No |
Clonazepam |
Benzodiazepine |
Antiseizure Drugs (2021) |
|
Lorazepam |
Yes |
Clopidogrel |
Antiplatelet Agent |
Antiplatelets (2015) |
|
Aspirin |
Yes |
Clotrimazole, topical |
Antifungal Agent, Imidazole Derivative |
Male Genitourinary Infections (Nov 2022) |
|
|
Yes |
Conjugated estrogen vaginal cream, (Premarin) |
===REMOVED from NCF=== (see Estrogen vaginal cream) |
NPTC Meeting Update (May 2018) |
Removed May 2018 |
Estrogen vaginal cream |
No |
Corticosteroid (Ophthalmic) - Low Potency |
Corticosteroid, Ophthalmic |
Ocular Treatments (2022) |
*Any product - see Form Brief for suggested products |
Artificial Tear substitute, Ophthalmic (Preservative Free); Ciprofloxacin, Ophthalmic Solution; Polymyxin B/trimethoprim, Ophthalmic Solution; Prednisolone, Ophthalmic Suspension |
Yes |
Corticosteroid (Topical) - Intermediate Potency |
Topical Corticosteroids |
Atopic Dermatitis (2020) |
*Any product* |
Corticosteroid (Topical) - Low Potency |
Yes |
Corticosteroid (Topical) - Low Potency |
Topical Corticosteroids |
Atopic Dermatitis (2020) |
*Any product* |
Corticosteroid (Topical) - Intermediate Potency |
Yes |
Corticosteroid, intranasal |
Intranasal Corticosteroid |
Allergic Rhinitis (2018) |
*Any product* |
|
Yes |
Corticosteroids (Topical) - High Potency (Class I and II) |
Topical Corticosteroids |
Alopecia Areata (2022) |
|
Corticosteroid (Topical) - Intermediate Potency; Corticosteroid (Topical) - Low Potency |
Yes |
Cyanocobalamin (Vitamin B12), oral |
Vitamin, Water Soluble |
Hematologic Supplements (2016) |
|
|
Yes |
Dedicated emergency contraceptive |
===REMOVED from NCF=== |
Contraception (2016) |
Removed Sept 2013 |
Levonorgestrel (Plan B One-Step®); Ulipristal |
No |
Dextroamphetamine / Amphetamine (immediate release) |
Central Nervous System Stimulant |
ADHD (Jan 2020) |
Pediatric use only |
|
Yes |
Dextroamphetamine / Amphetamine (long-acting) |
Central Nervous System Stimulant |
ADHD (Jan 2020) |
Pediatric use only |
|
Yes |
Diclofenac |
Nonsteroidal Anti-Inflammatory Drug |
NSAIDs (2014) |
*Any formulation* |
Ibuprofen; Indomethacin; Meloxicam; Naproxen |
Yes |
Dicyclomine |
Anticholinergic Agent |
Irritable Bowel Syndrome (2018) |
|
|
Yes |
Digoxin |
Antiarrhythmic Agent, Miscellaneous; Cardiac Glycoside |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
|
Yes |
Diltiazem |
Antihypertensive; Calcium Channel Blocker, Nondihydropyridine |
Hypertension (2022) |
|
Amlodipine |
Yes |
Divalproex |
Anticonvulsant, Miscellaneous |
Bipolar Disorder (2022) |
|
Carbamazepine; Lamotrigine; Levetiracetam; Phenytoin; Topiramate |
Yes |
Dolutegravir |
Antiretroviral, Integrase Inhibitor (Anti-HIV) |
HIV Updates (2020) |
For HIV treatment in pregnant patients |
Emtricitabine/tenofovir disoproxil fumarate; Raltegravir |
Yes |
Dolutegravir/Abacavir/Lamivudine |
Antiretroviral, Integrase Inhibitor (Anti-HIV) |
HIV Treatment (2019) |
*Note: HLA B5701 testing required prior to initiation |
Bictegravir/Emtricitabine/Tenofovir alafenamide; Dolutegravir; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir |
Yes |
Donepezil |
Acetylcholinesterase Inhibitor (Central) |
Alzheimer's disease (2019) |
5mg and 10mg strengths |
|
Yes |
Doxazosin |
Alpha1 Blocker; Antihypertensive |
Benign Prostatic Hypertrophy (Nov 2022) |
|
Prazosin; Tamsulosin |
Yes |
Doxycycline |
Antibiotic, Tetracycline |
STIs - PART 1 (2021) |
|
|
Yes |
Dulaglutide |
===REMOVED from NCF=== |
NPTC Meeting Update (2020) |
Removed Nov 2020 |
|
No |
Duloxetine |
Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist |
Bipolar Disorder (2022) |
|
Bupropion; Venlafaxine |
Yes |
Empagliflozin |
Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
|
Yes |
Emtricitabine/Tenofovir disoproxil fumarate |
Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV); Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV) |
HIV Pre-Exposure Prophylaxis (PrEP) (2018) |
For (1) Pre-Exposure HIV Prophylaxis, (2) Post-Exposure HIV Prophylaxis (with raltegravir) or (3) HIV Treatment (with raltegravir) in patients with contraindications for 1st line anti-HIV agents |
Raltegravir |
Yes |
Epinephrine Injection Devices (both 0.15mg and 0.3mg) |
Alpha-/Beta- Agonist |
Epinephrine Injection Devices (2020 |
Any device, auto-injector or pre-filled syringe |
|
Yes |
Escitalopram |
Antidepressant, Selective Serotonin Reuptake Inhibitor |
Bipolar Disorder (2022) |
|
Citalopram; Fluoxetine; Paroxetine; Sertraline |
Yes |
Estradiol for Injection |
Estrogen Derivative |
Gender Affirming Therapies (2022) |
Either valerate or cypionate product |
Estradiol tablets; Estradiol, transdermal |
Yes |
Estradiol tablets |
Estrogen Derivative |
Gender-Affirming Medications (2022) |
|
Estradiol for Injection; Estradiol, transdermal |
Yes |
Estradiol, transdermal |
Estrogen Derivative |
Gender Affirming Therapies (2022) |
*Any patch* |
Estradiol for Injection; Estradiol tablets |
Yes |
Estrogen vaginal cream |
Estrogen Derivative |
NPTC Meeting Update (May 2018) |
*Any product* |
Estradiol tablets |
Yes |
Etanercept |
Antirheumatic, Disease Modifying; Tumor Necrosis Factor (TNF) Blocking Agent |
TNF Inhibitors (2016) |
|
Adalimumab-bwwd (Hadlima™) |
Yes |
Ethambutol |
Antitubercular Agent |
Treatment of Tuberculosis (2021) |
|
Isoniazid; Pyrazinamide; Rifampin; Rifapentine |
Yes |
Ethinyl estradiol / Etonogestrel vaginal ring |
Contraceptive; Estrogen and Progestin Combination |
Contraception (2016) |
|
|
Yes |
Ethinyl estradiol / Norelgestromin, transdermal |
Contraceptive; Estrogen and Progestin Combination |
Contraception (2016) |
|
|
Yes |
Ethosuximide |
Anticonvulsant, Succinimide |
Anti-Seizure Drugs (2021) |
|
Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate |
Yes |
Etonogestrel, implant |
Contraceptive; Progestin |
Long Acting Reversible Contraception (2021) |
For use by a skilled and privileged provider |
Oral contraceptive pill, progestin only |
Yes |
Ezetimibe |
Antilipemic Agent, 2-Azetidinone |
Hyperlipidemia (2022) |
|
|
Yes |
Famotidine |
Histamine H2 Antagonist |
Fall 2022 NPTC Meeting Update |
|
|
Yes |
Fibric Acid Derivative |
===REMOVED from NCF=== |
Hyperlipidemia (2017) |
Removed Feb 2017 |
|
No |
Finasteride |
5 Alpha-Reductase Inhibitor |
Benign Prostatic Hypertrophy (Nov 2022) |
|
|
Yes |
Fluconazole, oral |
Antifungal Agent, Azole Derivative |
Male Genitourinary Infections (Nov 2022) |
|
|
Yes |
Fluoride, oral |
Nutritional Supplement |
Supplements in Oral Health (2016) |
*Any oral formulation* |
|
Yes |
Fluoxetine |
Antidepressant, Selective Serotonin Reuptake Inhibitor |
Bipolar Disorder (2022) |
|
Sertraline |
Yes |
Fluticasone / Salmeterol (Advair®) |
|
|
Removed Oct 2012 |
Fluticasone/salmeterol |
No |
Fluticasone/Salmeterol |
Beta2 Agonist, Long-Acting; Corticosteroid, Inhalant |
LABAs (2019) |
|
Mometasone (Asmanex®) |
Yes |
Folic Acid |
Vitamin, Water Soluble |
Pregnancy & Prenatal Care (2021) |
Any product containing >400 mcg / daily dose |
|
Yes |
Furosemide |
Antihypertensive |
Heart Failure with Preserved Ejection Fraction (HFpEF) (2022) |
|
|
Yes |
Gabapentin |
Anticonvulsant, Miscellaneous; GABA Analog |
Antiseizure Drugs (2021) |
|
|
Yes |
Gemfibrozil |
===REMOVED from NCF=== |
Dyslipidemia Guidelines Review (2014) |
Removed Feb 2014 |
|
No |
Glecaprevir/Pibrentasvir (Mavyret®) |
Antihepaciviral |
HCV Treatment (2018) |
|
Ledipasvir/sofosbuvir (Harvoni®); Sofosbuvir/velpatasvir (Epclusa®) |
Yes |
Glipizide |
Antidiabetic Agent; Sulfonylurea |
Diabetes Treatment Overview (2017) |
|
|
Yes |
Glucagon |
Antidote; Hypoglycemia |
Glucagon Products Review (2021) |
For outpatient use |
|
Yes |
Glucose, oral |
Antidote |
Glucagon Products Review (2021) |
Any formulation |
Glucagon |
Yes |
Glyburide |
===REMOVED from NCF=== (see Glipizide) |
Sulfonylureas (2015) |
Removed May 2015 |
Glipizide |
No |
H1 Antagonist (2nd generation), long-acting |
Histamine H1 Antagonist, Second Generation |
Allergic Rhinitis (2018) |
*Any product* |
|
Yes |
Haloperidol decanoate |
Antipsychotic, Typical (First Generation) - Injectable |
Long-Acting Injectable Antipsychotics (2020) |
Injectable |
Aripiprazole lauroxil |
Yes |
Hydrochlorothiazide |
Antihypertensive; Thiazide Diuretic |
Hypertension (2022) |
|
Chlorthalidone |
Yes |
Hydroxychloroquine |
Antimalarial |
Non-biologic DMARDs (2016) |
|
Leflunomide; Methotrexate; Sulfasalazine |
Yes |
Hydroxyzine |
Histamine H1 Antagonist, First Generation |
Anxiety Disorders (2021) |
|
|
Yes |
Ibuprofen |
Nonsteroidal Anti-Inflammatory Drug |
NSAIDs (2014) |
|
Diclofenac; Indomethacin; Meloxicam; Naproxen |
Yes |
Imipramine |
===REMOVED from NCF=== (see Nortriptyline) |
Antidepressant Use in Chronic Pain (2014) |
Removed May 2014 |
Nortriptyline |
No |
Indomethacin |
Nonsteroidal Anti-Inflammatory Drug |
NSAIDs (2014) |
|
Diclofenac; Ibuprofen; Meloxicam; Naproxen |
Yes |
Insulin aspart (NovoLog®) |
Insulin, Rapid-Acting |
Diabetes Treatment Overview (2017) |
*Branded product*; Pen Device |
|
Yes |
Insulin aspart / Insulin aspart protamine (NovoLog® Mix 70/30) |
Insulin, Combination (70/30 Mix) |
Diabetes Treatment Overview (2017) |
*Branded product*; Pen Device |
|
Yes |
Insulin detemir (Levemir®) |
===REMOVED from NCF=== |
|
Removed October 2023 |
|
No |
Insulin glargine (Lantus®) |
===REMOVED from NCF=== (see Insulin detemir) |
NPTC Meeting Update (May 2019) |
Removed May 2019 |
Insulin detemir (Levemir®) |
No |
Insulin glargine, Any |
Insulin, Long-Acting |
Long-Acting Insulins & Biosimilars (2021) |
*Biosimilars of insulin glargine are intended to be included for consideration |
|
Yes |
Insulin NPH (NovoLIN® N) |
Insulin, Intermediate-Acting |
Diabetes Treatment Overview (2017) |
*Branded product* |
|
Yes |
Insulin NPH / Regular human insulin (NovoLIN® 70/30) |
Insulin, Combination (70/30 Mix) |
Diabetes Treatment Overview (2017) |
*Branded product* |
|
Yes |
Insulin Regular human (NovoLIN® R) |
Insulin, Short-Acting |
Diabetes Treatment Overview (2017) |
*Branded product* |
|
Yes |
Intrauterine device, copper |
Contraceptive |
Long Acting Reversible Contraception (2021) |
*Any product*; For use by a skilled and privileged provider |
Intrauterine device, levonorgestrel |
Yes |
Intrauterine device, levonorgestrel |
Contraceptive, Progestin |
Long Acting Reversible Contraception (2021) |
*Any product*; For use by a skilled and privileged provider |
Intrauterine device, copper |
Yes |
Ipratropium, MDI |
===REMOVED from NCF=== |
COPD Inhalers (2015) |
Removed Aug 2015 |
Albuterol, metered dose inhaler (MDI); Tiotropium (Spiriva®) |
No |
Iron, oral |
Iron Salt |
Pregnancy & Prenatal Care (2021) |
*Any oral formulation* |
|
Yes |
Isoniazid |
Antitubercular Agent |
Treatment of Tuberculosis (2021) |
|
Ethambutol; Pyrazinamide; Rifampin; Rifapentine |
Yes |
Isosorbide dinitrate |
===REMOVED from NCF=== (see Isosorbide mononitrate) |
|
Removed Aug 2013 |
Isosorbide mononitrate |
No |
Isosorbide mononitrate |
Antianginal Agent; Vasodilator |
Anti-Anginal Treatment (2013) |
|
Nitroglycerin patch |
Yes |
Lactulose |
Ammonium Detoxicant; Laxative, Osmotic |
Hepatic Encephalopathy (2020) |
|
Polyethylene glycol |
Yes |
Lamotrigine |
Anticonvulsant, Miscellaneous |
Bipolar Disorder (2022) |
|
Carbamazepine; Divalproex; Levetiracetam; Phenytoin; Topiramate |
Yes |
Laxative, bulk-forming |
Bulk-forming Laxative |
Added July 2011 (Constipation) |
*Any product* |
|
Yes |
Laxative, stimulant |
Stimulant Laxative |
Added July 2011 (Constipation) |
*Any product* |
|
Yes |
Ledipasvir/Sofosbuvir (Harvoni®) |
Antihepaciviral |
HCV Treatment (2018) |
|
Glecaprevir/Pibrentasvir (Mavyret®); Sofosbuvir/velpatasvir (Epclusa®) |
Yes |
Leflunomide |
Antirheumatic, Disease Modifying |
Non-biologic DMARDs (2016) |
|
Hydroxychloroquine; Methotrexate; Sulfasalazine |
Yes |
Letrozole |
Antineoplastic Agent, Aromatase Inhibitor |
NPTC Update Spring 2021 |
|
|
Yes |
Leuprolide |
Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist |
Treatment of Prostate Cancer (Nov 2022) |
**Any depot form** |
|
Yes |
Levetiracetam |
Anticonvulsant, Miscellaneous |
Antiseizure Drugs (2021) |
|
Carbamazepine; Divalproex; Lamotrigine; Phenytoin; Topiramate |
Yes |
Levonorgestrel (Plan B One-Step®) |
Contraceptive, Progestin |
Contraception (2016) |
*Branded product* |
Ulipristal |
Yes |
Levothyroxine |
Thyroid Agent |
Originally added 2004 |
|
|
Yes |
Liraglutide -or- Semaglutide |
===REMOVED from NCF=== |
|
Removed October 2023 |
|
No |
Lisinopril |
Antihypertensive, Angiotensin-Converting Enzyme Inhibitor |
Hypertension (2022) |
|
|
Yes |
Lithium |
Antimanic Agent |
Bipolar Disorder (2022) |
|
|
Yes |
Long-acting monoclonal antibodies, All ACIP-recommended |
Immune Globulin; Monoclonal Antibody |
Prevention of RSV (2023) |
For example: nirsevimab (Beyfortus®) |
|
Yes |
Loperamide |
Antidiarrheal |
Irritable Bowel Syndrome (2018) |
|
|
Yes |
Lopinavir / Ritonavir (Kaletra®) |
===REMOVED from NCF=== (see Emtricitabine/tenofovir) |
HIV PrEP (2018) |
Removed August 2013 |
|
No |
Lorazepam |
Benzodiazepine |
Alcohol Withdrawal Syndrome (2015) |
|
Clonazepam |
Yes |
Losartan |
Antihypertensive, Angiotensin II Receptor Blocker |
Hypertension (2022) |
|
|
Yes |
Lovastatin |
===REMOVED from NCF=== |
Dyslipidemia Guidelines Review (2014) |
Removed April 2012 |
Atorvastatin; Pravastatin; Rosuvastatin; Simvastatin |
No |
Low-molecular weight heparin |
Low-molecular Weight Heparin |
VTE Prophylaxis (2011) |
*Any product* |
|
Yes |
Medroxyprogesterone acetate, injection (IM and SC formulations) |
Contraceptive, Progestin (Injection/Depot) |
SC Depot Medroxyprogesterone (2023) |
Both SC and IM formulations should be made available |
Medroxyprogesterone, oral |
Yes |
Medroxyprogesterone, oral |
Contraceptive; Progestin |
Polycystic Ovarian Syndrome (2017) |
|
Medroxyprogesterone acetate, injection; Oral contraceptive pill, progestin only |
Yes |
Meloxicam |
Nonsteroidal Anti-Inflammatory Drug |
NSAIDs (2014) |
|
Diclofenac; Ibuprofen; Indomethacin; Naproxen |
Yes |
Memantine |
N-Methyl-D-Aspartate (NMDA) Receptor Antagonist |
Alzheimer's disease (2019) |
|
|
Yes |
Mercaptopurine -OR- Azathioprine |
Immunosuppresant Agent |
Inflammatory Bowel Disease (2023) |
|
Methotrexate; Sumatriptan |
Yes |
Mesalamine, oral |
5-Aminosalicylic Acid Derivative |
Inflammatory Bowel Disease (2023) |
Once-Daily Formulation |
Sulfasalazine |
Yes |
Metformin |
Antidiabetic Agent; Biguanide |
Diabetes Treatment Overview (2017) |
|
|
Yes |
Methimazole |
Antithyroid Agent; Thioamide |
Hyperthyroidism (2021) |
|
Propylthiouracil |
Yes |
Methotrexate |
Antineoplastic Agent; Antirheumatic; Disease Modifying; Immunosuppresant Agent |
Non-biologic DMARDs (2016) |
|
Hydroxychloroquine; Leflunomide; Sulfasalazine |
Yes |
Methylphenidate (immediate release) |
Central Nervous System Stimulant |
ADHD (Jan 2020) |
Pediatric use only |
Methylphenidate (long-acting) |
Yes |
Methylphenidate (long-acting) |
Central Nervous System Stimulant |
ADHD (Jan 2020) |
Pediatric use only |
Methylphenidate (immediate release) |
Yes |
Metoprolol succinate |
Antihypertensive; Beta-Blocker, Beta1 Selective |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
Atenolol; Carvedilol, immediate-release; Propranolol |
Yes |
Metoprolol tartrate |
Antihypertensive; Beta-Blocker, Beta1 Selective |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
Atenolol; Carvedilol, immediate-release; Metoprolol succinate |
Yes |
Metronidazole, oral |
Antibiotic, Miscellaneous |
2021 CDC Guidelines for Sexually Transmitted Infections (2021) |
|
Tinidazole |
Yes |
Metronidazole, topical |
Antibiotic, Topical |
Rosacea (2022) |
|
|
Yes |
Moisturizers (both cream- AND petroleum-based) |
Skin and Mucous Membrane Agent, Miscellaneous; Topical Skin Product |
Atopic Dermatitis (2020) |
|
Corticosteriods (Topical) - High potency (Class I and II); Corticosteroid (Topical) - Intermediate potency; Corticosteroid (Topical) - Low potency; Tacrolimus |
Yes |
Mometasone (Asmanex®) |
Corticosteroid, Inhalant |
Asthma & COPD Guidelines Review (2019) |
*Branded product* |
|
Yes |
Mometasone / Formoterol (Dulera®) |
===REMOVED from NCF=== (see Fluticasone/salmeterol) |
LABAs (2019) |
Removed June 2019 |
Fluticasone/salmeterol |
No |
Montelukast |
Leukotriene Receptor Antagonist |
Asthma & COPD Guidelines Review (2019) |
|
|
Yes |
Mupirocin |
Antibiotic, Topical |
Skin & Soft Tissue Infections (2021) |
|
|
Yes |
Naloxone |
Antidote; Opioid Antagonist |
Opioid Use Disorder (2018) |
|
|
Yes |
Naltrexone, extended-release for injection |
Antidote; Opioid Antagonist |
Opioid Use Disorder (2018) |
|
|
Yes |
Naltrexone, oral |
Antidote; Opioid Antagonist |
Alcohol Use Disorder (2022) |
|
Naloxone |
Yes |
Naproxen |
Nonsteroidal Anti-Inflammatory Drug |
NSAIDs (2014) |
|
Diclofenac; Ibuprofen; Indomethacin |
Yes |
Niacin extended release (Niaspan®) |
===REMOVED from NCF=== |
Hyperlipidemia (2017) |
Removed Feb 2017 |
|
No |
Nicotine replacement therapy (NRT), combination |
Smoking Cessation Aid |
Nicotine Dependence (2020) |
Combination NRT (nicotine patches + any short-acting NRT product) |
Bupropion; Varenicline |
Yes |
Nifedipine (controlled or extended release) |
===REMOVED from NCF=== |
Calcium Channel Blockers (2014) |
Removed August 2014 |
Amlodipine |
No |
Nirmatrelvir and Ritonavir (Paxlovid®) |
Antiviral Agent; Cytochrome P-450 Inhibitor |
COVID-19 Update (2023) |
|
|
Yes |
Nitrofurantoin |
Antibiotic, Miscellaneous |
Urinary Tract Infections (2021) |
|
|
Yes |
Nitroglycerin 0.4 milligrams, sublingual |
Antianginal Agent; Antidote, Extravasation; Vasodilator |
Anti-Anginal Treatment (2013) |
|
Isosorbide mononitrate; Nitroglycerin patch |
Yes |
Nitroglycerin patch |
Antianginal Agent; Antidote, Extravasation; Vasodilator |
Anti-Anginal Treatment (2013) |
|
Isosorbide mononitrate |
Yes |
Norgestrel 0.075mg OTC tablets (Opill®) |
Contraceptive, Progestin |
Norgestrel OTC - Opill (2023) |
|
Oral contraceptive pill, progestin only (prescription) |
Yes |
Nortriptyline |
Antidepressant, Tricyclic |
Bipolar Disorder (2022) |
|
Amitriptyline |
Yes |
Omeprazole (enteric coated) |
===REMOVED from NCF=== (see Proton Pump Inhibitor) |
Long-Term Use of PPIs (2014) |
Removed Feb 2014 |
Proton Pump Inhibitor |
No |
Ondansetron |
Antiemetic; Selective 5-HT3 Receptor Antagonist |
Antiemetic Agents (2021) |
|
|
Yes |
Ophthalmic Prostaglandin Analog |
Ophthalmic Prostaglandin Analog |
Ophth Prostaglandin Analogs (2018) |
*Any product* |
|
Yes |
Oral contraceptive pill, extended cycle |
Contraceptive |
Contraception (2016) |
*Any product* |
|
Yes |
Oral contraceptive pill, monophasic: 20mcg EE (low) |
Contraceptive |
Contraception (2016) |
*Any product* |
|
Yes |
Oral contraceptive pill, monophasic: 30-35mcg EE (medium) |
Contraceptive |
Contraception (2016) |
*Any product* |
|
Yes |
Oral contraceptive pill, progestin only (prescription) |
Contraceptive, Progestin |
Norgestrel OTC - Opill (2023) |
*Any product* |
|
Yes |
Oral contraceptive pill, triphasic |
Contraceptive |
Contraception (2016) |
*Any product* |
|
Yes |
Oseltamivir |
Antiviral Agent; Neuraminidase Inhibitor |
Treatment of Influenza (2019) |
|
|
Yes |
Oxcarbazepine |
Anticonvulsant, Miscellaneous |
Bipolar Disorder (2022) |
|
Carbamazepine; Clonazepam; Divalproex; Gabapentin; Lamotrigine; Levetiracetam; Phenytoin; Topiramate |
Yes |
Oxybutynin, extended-release |
Antispasmodic Agent, Urinary |
Antimuscarinics (2019) |
|
Oxybutynin, Immediate-release |
Yes |
Oxybutynin, immediate-release |
Antispasmodic Agent, Urinary |
Antimuscarinics (2019) |
|
Oxybutynin, extended-release |
Yes |
Paroxetine |
Antidepressant, Selective Serotonin Reuptake Inhibitor |
Bipolar Disorder (2022) |
|
Citalopram; Escitalopram; Fluoxetine; Sertraline |
Yes |
Penicillin G benzathine |
Antibiotic, Penicillin |
STIs - PART 1 (2021) |
|
Amoxicillin; Amoxicillin and Clavulanate; Penicllin V potassium |
Yes |
Penicillin V potassium |
Antibiotic, Penicillin |
Outpatient Abx Stewardship & URIs (2021) |
Pediatric and Adult oral formulations |
Amoxicillin; Amoxicillin and Clavulanate; Penicillin G benzathine |
Yes |
Permethrin 1% |
Antiparasitic Agent, Topical; Pediculocide; Scabicidal Agent |
Sexually Transmitted Infections, Part III (2022) |
*Any formulation* |
Permethrin 5% cream |
Yes |
Permethrin 5% cream |
Antiparasitic Agent, Topical; Pediculocide; Scabicidal Agent |
Sexually Transmitted Infections, Part III (2022) |
|
Permethrin 1%, any formulation |
Yes |
Phentermine and Topiramate ER (**REMS drug**) |
===REMOVED from NCF=== |
|
Removed October 2023 |
|
No |
Phenytoin |
Anticonvulsant, Hydantoin |
Antiseizure Drugs (2021) |
|
Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Topiramate |
Yes |
Phosphodiesterase 5 (PDE5) Inhibitor |
===REMOVED from NCF=== |
Erectile Dysfunction (Nov 2022) |
Removed November 2022 |
|
No |
Pioglitazone |
Antidiabetic Agent, Thiazolidinedione |
Thiazolidinediones (2017) |
|
|
Yes |
Polyethylene glycol |
Laxative, Osmotic |
Irritable Bowel Syndrome (2018) |
*Any product* |
Lactulose |
Yes |
Polymyxin B/Trimethoprim, ophthalmic solution |
Antibiotic, Ophthalmic |
Ocular Treatments (2022) |
|
Artificial Tear substitute, ophthalmic (preservative free); Ciprofloxacin, ophthalmic solution; Corticosteroid (Ophthalmic) - Low Potency |
Yes |
Pramipexole |
Anti-Parkinson Agent, Dopamine Agonist |
Insomnia/Sleep Medications (2021) |
|
|
Yes |
Pravastatin |
Antilipemic Agent, HMG-CoA Reductase Inhibitor |
Hyperlipidemia (2022) |
|
Atorvastatin; Rosuvastatin; Simvastatin |
Yes |
Prazosin |
Alpha1 Blocker; Antihypertensive |
Post Traumatic Stress Disorder (2021) |
|
Doxazosin; Tamsulosin |
Yes |
Prednisolone acetate, ophthalmic suspension |
Corticosteroid, Ophthalmic |
Ocular Treatments (2022) |
|
Artificial Tear substitute, ophthalmic (preservative free); Ciprofloxacin, ophthalmic solution; Corticosteroid (Ophthalmic) - Low Potency; Polymyxin B/Trimethoprim, ophthalmic solution |
Yes |
Prednisone |
Corticosteroid, Systemic |
Atopic Dermatitis (2020) |
|
|
Yes |
Prenatal Multivitamin |
Vitamin |
Pregnancy & Prenatal Care (2021) |
Must contain >400 mcg of folic acid/dose |
|
Yes |
Propranolol |
Antihypertensive; Beta-Blocker, Non-Selective |
Migraine Prevention (2019) |
|
Atenolol |
Yes |
Propylthiouracil |
Antithyroid Agent; Thioamide |
Hyperthyroidism (2021) |
|
Methimazole |
Yes |
Proton Pump Inhibitor |
Proton Pump Inhibitor |
GERD & PUD (2018) |
*Any product* |
|
Yes |
Pyrazinamide |
Antitubercular Agent |
Treatment of Tuberculosis (2021) |
|
Ethambutol; Isoniazid; Rifampin |
Yes |
Pyridoxine (Vitamin B6) |
Vitamin, Water Soluble |
Pregnancy & Prenatal Care (2021) |
|
|
Yes |
Raltegravir |
Antiretroviral, Integrase Inhibitor (Anti-HIV) |
HIV Treatment (2019) |
For (1) HIV Post-Exposure Prophylaxis (with emtricitabine/ tenofovir DF) or (2) HIV Treatment (with emtricitabine/tenofovir DF) in patients with contraindications for 1st line anti-HIV agents |
Emtricitabine/tenofovir disoproxil fumarate |
Yes |
Ranitidine |
===REMOVED from NCF=== |
|
Removed August 2022 |
|
No |
Rifampin |
Antitubercular Agent |
Treatment of Tuberculosis (2021) |
|
Ethambutol; Isoniazid; Pyrazinamide; Rifapentine |
Yes |
Rifapentine |
Antitubercular Agent |
Treatment of Tuberculosis (2021) |
|
Ethambutol; Isoniazid; Pyrazinamide; Rifampin |
Yes |
Rifaximin |
Antibiotic, Rifamycin |
Hepatic Encephalopathy (2020) |
After failure of, or intolerance to, lactulose monotherapy as indicated for hepatic encephalopathy |
Lactulose |
Yes |
Rosuvastatin |
Antilipemic Agent, HMG-CoA Reductase Inhibitor |
Hyperlipidemia (2022) |
|
Atorvastatin; Pravastatin; Simvastatin |
Yes |
Sacubitril and Valsrtan |
Angiotensin II Receptor Blocker; Neprilysin Inhibitor |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
|
Yes |
Salmeterol (Serevent®) |
===REMOVED from NCF=== |
Inhaled Anticholinergics (2011) |
Removed Sept 2011 |
|
No |
Salsalate |
Salicylate |
Added June 2008 (NSAIDs) |
|
|
Yes |
Saxagliptin |
===REMOVED from NCF=== (see Alogliptin) |
DPP-IV Inhibitors (2019) |
Removed Feb 2019 |
Alogliptin |
No |
Semaglutide (Ozempic®) |
Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist |
GLP-1 & GLP-1/GIP Receptor Agonists for DM2 and Obesity (2023) |
Subcutaneous formulation only |
|
Yes |
Semaglutide (Wegovy®) -OR- Tirzepatide (Zepbound™) |
Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like Peptide (GLP-1) Receptor Agonist |
NPTC Update (Jan 2024) |
For weight management, with recommended local adoption of use criteria |
|
Yes |
Semaglutide, dulaglutide or liraglutide |
===REMOVED from NCF=== |
|
Dulaglutide removed from NCF; liraglutide and semaglutide remain on NCF |
|
No |
Serotonin 5-HT1 agonist (Triptan) |
Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist |
Acute Migraine (2021) |
Any two (2) triptan medications are required, one must be sumatriptan |
Sumatriptan |
Yes |
Sertraline |
Antidepressant, Selective Serotonin Reuptake Inhibitor |
Bipolar Disorder (2022) |
|
Citalopram; Escitalopram; Fluoxetine; Paroxetine |
Yes |
Sevelamer carbonate |
Phosphate Binder |
Phosphate Binders (2018) |
For patients on dialysis who cannot use calcium-based phosphate binders due to hypercalcemia |
Calcium |
Yes |
Sildenafil |
Phosphodiesterase-5 Enzyme Inhibitor |
Erectile Dysfunction (Nov 2022) |
|
Tadalafil |
Yes |
Simvastatin |
Antilipemic Agent, HMG-CoA Reductase Inhibitor |
Hyperlipidemia (2022) |
|
Atorvastatin; Pravastatin; Rosuvastatin |
Yes |
Sofosbuvir/Velpatasvir (Epclusa®) |
Antihepaciviral |
HCV Treatment (2018) |
|
Glecaprevir/Pibrentasvir (Mavyret®); Ledipasvir/Sofosbuvir (Harvoni®) |
Yes |
Spironolactone |
Antihypertensive; Mineralocorticoid Receptor Antagonists; Potassium Sparing Diuretic |
Heart Failure with Reduced Ejection Fraction (HFrEF) (2022) |
|
|
Yes |
Sulfasalazine |
5-Aminosalicylic Acid Derivative |
Inflammatory Bowel Disease (2018) |
|
Hydroxychloroquine; Leflunomide; Methotrexate |
Yes |
Sulindac |
===REMOVED from NCF=== |
NSAIDs in Chronic Pain (2014) |
Removed May 2014 |
Diclofenac; Ibuprofen; Indomethacin; Meloxicam; Naproxen |
No |
Sumatriptan |
Antimigraine Agent; Serotonin 5-HT 1B/1D Receptor Agonist |
Acute Migraine (2021) |
Any two (2) triptan medications are required, one must be sumatriptan |
|
Yes |
Sunscreen, Sun Protection Factor (SPF) 30 or greater |
Ultraviolet light protectant, topical |
Rosacea Treatment (2022) |
|
|
Yes |
Tacrolimus, topical |
Calcineurin Inhibitor; Immunosuppressant Agent; Topical Skin Product |
Atopic Dermatitis (2020) |
|
Corticosteriods (Topical) - High Potency (Class I and II); Corticosteroid (Topical) - Intermediate Potency; Corticosteroid (Topical) - Low Potency; Moisturizers (both cream- AND petroleum-based) |
Yes |
Tadalafil |
Phosphodiesterase-5 Enzyme Inhibitor |
Erectile Dysfunction (Nov 2022) |
|
Sildenafil |
Yes |
Tamoxifen |
Antineoplastic Agent, Estrogen Receptor Antagonist; Selective Estrogen Receptor Modulator |
NPTC Update Spring 2021 |
|
|
Yes |
Tamsulosin |
Alpha1 Blocker |
Benign Prostatic Hypertrophy (Nov 2022) |
|
Doxazosin; Prazosin |
Yes |
Terazosin |
===REMOVED from NCF=== |
Prazosin in PTSD (2012) |
Removed Jan 2012 |
Doxazosin; Prazosin; Tamsulosin |
No |
Testosterone (**REMS Drug**) |
Androgen |
Male Hypogonadism (2022) |
Any formulation; Certain formulations (i.e., undecoanate) have REMS requirements |
|
Yes |
Tinidazole |
Antibiotic, Miscellaneous |
2021 CDC Guidelines for Sexually Transmitted Infections (2021) |
|
Metronidazole |
Yes |
Tiotropium (Spiriva®) |
Long-Acting Anticholinergic Agent |
Long Acting Muscarinic Antagonists (2019) |
*Branded product* |
|
Yes |
Tirzepatide (Zepbound™) -OR- Semaglutide (Wegovy®) |
Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like Peptide (GLP-1) Receptor Agonist |
NPTC Update (Jan 2024) |
For weight management, with recommended local adoption of use criteria |
|
Yes |
Topiramate |
Anticonvulsant, Miscellaneous |
Alcohol Use Disorder (2022) |
|
Carbamazepine; Divalproex; Lamotrigine; Levetiracetam; Phenytoin |
Yes |
Torsemide -OR- Bumetanide |
Antihypertensive |
Heart Failure with Preserved Ejection Fraction (HFpEF) (2022) |
|
Bumetanide -OR- Torsemide; Furosemide |
Yes |
Trazodone |
===REMOVED from NCF=== |
Insomnia (2015) |
Removed Oct 2015 |
|
No |
Tretinoin, topical |
Topical Skin Product, Acne |
Treatment of Acne vulgaris (2020) |
*Any product* |
|
Yes |
Trimethoprim-Sulfamethoxazole |
Antibiotic, Miscellaneous |
Skin & Soft Tissue Infections (2021) |
|
|
Yes |
Trospium |
===REMOVED from NCF=== (see Oxybutynin ER, IR) |
Antimuscarinics (2019) |
Removed Feb 2019 |
Oxybutynin, Extended-release; Oxybutynin, Immediate-release |
No |
Ulipristal |
Contraceptive; Progestin Receptor Modulator |
Contraception (2016) |
|
Levonorgestrel (Plan B One-Step®) |
Yes |
Umeclidinium/Vilanterol |
Long-Acting Muscarinic Antagonist (LAMA) / Long-Acting Beta2 Agonist (LABA) |
LAMAs (2019) |
|
Tiotropium (Spiriva®) |
Yes |
Vaccines, All ACIP-recommended |
Vaccines |
Vaccine (2011) |
All ACIP recommended vaccines for routine use in accordance with ACIP guidelines |
|
Yes |
Valacyclovir |
Antiviral Agent, Oral |
2021 CDC Guidelines for Sexually Transmitted Infections (2021) |
|
|
Yes |
Vancomycin, oral |
Glycopeptide |
Clostridioides Difficile (2023) |
|
Metronidazole, oral |
Yes |
Varenicline |
Partial Nicotine Agonist, Smoking Cessation Aid |
Nicotine Dependence (2020) |
|
Bupropion |
Yes |
Venlafaxine |
Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor/Antagonist |
Bipolar Disorder (2022) |
|
Bupropion; Duloxetine |
Yes |
Verapamil |
===REMOVED from NCF=== (see Diltiazem) |
Calcium Channel Blockers (2014) |
Removed August 2014 |
Diltiazem |
No |
Vitamin D Analog, topical |
Vitamin D Analog |
Psoriasis (2018) |
*Any product* |
|
Yes |
Vitamin D, Any |
Vitamin D Analog |
Vitamin D Analogues in CKD (2010) |
*Any product* |
|
Yes |
Warfarin |
Anticoagulant; Vitamin K Antagonist |
Direct Oral Anticoagulants (2017) |
|
Apixaban; Low-molecular weight heparin |
Yes |